X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Totum-63
Therapeutic Area: Endocrinology Product Name: Totum-63
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
EASD has selected the positive results of the international Phase II clinical study on TOTUM-63 in prediabetes to be presented next September in its 56th annual meeting. These results were selected by the American Diabetes Association last June 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Totum-63
Therapeutic Area: Endocrinology Product Name: Totum-63
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The REVERSE-IT study will include 600 patients with fasting hyperglycemia ranging from prediabetes to untreated early stage Type 2 Diabetes. The study should confirm the efficacy of TOTUM-63 - at a dose of 5g/day for 6 months.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
